AAV2sFLT01 (Applied Genetic Technologies/Genzyme)

N/A

Report date: 2023/10/26 16:21:08

Base Information

Drug NameAAV2sFLT01 (Applied Genetic Technologies/Genzyme)

Drug Alias Nameage-related macular degeneration gene therapy - Applied Genetic Technologies/Genzymeanti vascular endothelial growth factor (VEGF) gene therapy - Applied Genetic Technologies/GenzymeGZ-402663AAV2-sFLT01sFLT-01

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsRetinal NeovascularizationMacular DegenerationRetinal Degeneration +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenzyme Corp Applied Genetic

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenzyme Corp

Active IndicationsN/A

Inactive IndicationsRetinal NeovascularizationMacular DegenerationRetinal Degeneration +[4]

Other Information

ATC CodeN/A